CD200R1, transmits inhibitory signals that suppress macrophage and T cell activation, contributing to immune evasion. Ucenprubart’s blockade of the CD200–CD200R1 axis aims to restore immune cell function, promote antigen presentation, and overcome resistance to existing checkpoint therapies. Its IgG4 isotype minimizes Fc-mediated effector functions, focusing on checkpoint modulation rather than cell depletion.